Access to AstraZeneca’s hyperkalaemia treatment Lokelma has been expanded across England and Wales. AstraZeneca announced the National Institute for Health and Care Excellence (NICE) had issued a draft recommendation for lokelma (sodium zirconium cyclosilicate). Under the new willingness-to-pay threshold, more than double the number of patients could be eligible for treatment in England and Wales. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!